<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5323">
  <stage>Registered</stage>
  <submitdate>9/05/2015</submitdate>
  <approvaldate>9/05/2015</approvaldate>
  <nctid>NCT02460224</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.</studytitle>
    <scientifictitle>A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CLAG525X2101C</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LAG525
Treatment: drugs - PDR001

Experimental: Arm A - single agent treatment arm with LAG525

Experimental: Arm B: combination of LAG525 and PDR001 - combination treatment arm with LAG525 and PDR001

Experimental: Arm C - Single agent treatment arm with LAG525 in Japanese pts


Treatment: drugs: LAG525
study drug 1

Treatment: drugs: PDR001
study drug 2

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phase I part: Incidence of dose limiting toxicities (DLTs) - A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment with single agent LAG525 or within the first two cycles of treatment with the combination of LAG525 and PDR001</outcome>
      <timepoint>30 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Phase II part: Overall response Rate per RECIST V1.1 - Overall Response Rate (ORR) is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on local Investigator assessment, as defined in RECIST v1.1. Estimation of the true ORR in this part of the study will be based upon the observed ORR for patients in full analysis set.</outcome>
      <timepoint>30 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>AUC - Characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Presence and/ or concentration of anti-LAG525 and anti-PDR001 antibodies - Assess emergence of anti-LAG525, and anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of single agent LAG525 given alone or in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of PD-L1, Lymphocyte activation gene-3 LAG-3 expression - Assess potential predictors of efficacy of single agent LAG525 and the combination of LAG525 and PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response Rate (ORR) - Evaluate the preliminary antitumor activity per RECIST as well as per immune related Response Criteria (irRC) on single agent LAG525 given alone or in combination of PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Expression of IFN-? immune-related genes by mRNA profiling - Assess the pharmacodynamic effect of single agent LAG525 and the combination of LAG525 and PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety incidence of Adverse Events (AEs - Characterize the safety of single agent LAG525 given alone and in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability measured by dose interruptions - Characterize the tolerability of single agent LAG525 given alone and in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival (PFS) - Evaluate the preliminary antitumor activity per RECIST as well as per immune related Response Criteria (irRC) on single agent LAG525 given alone or in combination of PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) - Evaluate the preliminary antitumor activity per RECIST as well as per immune related Response Criteria (irRC) on single agent LAG525 given alone or in combination of PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control rate (DCR) - Evaluate the preliminary antitumor activity per RECIST as well as per immune related Response Criteria (irRC) on single agent LAG525 given alone or in combination of PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety measuresd by incidence of Serious Adverse Events (SAEs) - Characterize the safety of single agent LAG525 given alone and in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax - Characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tmax - Characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>half-life - Characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability measured by dose reductions - Characterize the tolerability of single agent LAG525 given alone and in combination with PDR001</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Phase I part:

        - Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease
        as determined by RECIST version 1.1 (refer to Appendix 1), who have progressed despite
        standard therapy or are intolerant of standard therapy, or for whom no standard therapy
        exists

        Phase II part:

          -  Patients with advanced/metastatic solid tumors, with at least one measurable lesion as
             determined by RECIST version 1.1, who have had disease progression following their
             last prior therapy and fit into one of the following groups:

          -  Group 1: NSCLC

          -  Group 2: Melanoma

          -  Group 3: Renal cancer

          -  Group 4: Mesothelioma

          -  Group 5: TNBC

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status = 1

          -  Patient must have a site of disease amenable to biopsy, and be a candidate for tumor
             biopsy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of severe hypersensitivity reactions to study treatment ingredients or other
             mAbs

          -  Active, known or suspected autoimmune disease

          -  Active infection requiring systemic antibiotic therapy

          -  HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Patients receiving chronic treatment with systemic steroid therapy, other than
             replacement-dose corticosteroids in the setting of adrenal insufficiency

          -  Patients receiving systemic treatment with any immunosupressive medication

          -  Use of live vaccines against infectious disease within 4 weeks of initiation of study
             treatment

          -  Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.

          -  Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that
             require local CNS-directed therapy or increasing doses of corticosteroids within the
             prior 2 weeks

          -  History of drug-induced pneumonitis or current pneumonitis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>17/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>416</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>28/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Westmead</hospital>
    <hospital>Novartis Investigative Site - Heidelberg</hospital>
    <postcode>2145 - Westmead</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>WÃ¼rzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to characterize the safety, tolerability, pharmacokinetics (PK),
      pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination
      with PDR001 to adult patients with solid tumors. The study consists of a dose escalation
      phase (I) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D)
      for LAG525 as a single agent and in combination with PDR001, and a dose expansion phase (II)
      which will characterize treatment of LAG525 as a single agent and in combination with PDR001
      at the MTD or RP2D.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02460224</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address />
      <phone>1-888-669-6682</phone>
      <fax />
      <email>Novartis.email@novartis.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>